NAMS
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V. (NAMS) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Momentum (D+). The rating has held at C for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C (2.4) | C- (1.9) | B (3.5) | D+ (1.7) | C+ (2.6) | C (2.4) |
| 2026-11-06 | D (1.2) | C+ (2.5) | B (3.4) | D+ (1.7) | C+ (2.7) | C (2.3) |
| 2026-10-30 | D- (1.0) | C+ (2.5) | B (3.4) | C- (2.0) | C+ (2.7) | C (2.3) |
| 2026-10-23 | D- (0.9) | C+ (2.5) | B (3.4) | D+ (1.6) | C+ (2.6) | C (2.2) |
| 2026-10-16 | D- (1.0) | C+ (2.5) | B (3.4) | D (1.4) | C+ (2.6) | C (2.2) |